Published in Clin Drug Investig on June 01, 2013
Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf (2014) 0.92
A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. Pain Med (2015) 0.82
In response to Gudin et al - Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med (2016) 0.75
Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med (2007) 3.56
Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct J (2010) 2.06
Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs (2010) 1.70
Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain (2007) 1.48
Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse (2011) 1.40
The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother (2004) 1.39
Palatal perforation associated with intranasal prescription narcotic abuse. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2005) 1.34
Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev (2005) 1.33
Complications of intranasal prescription narcotic abuse. Ann Otol Rhinol Laryngol (2002) 1.32
Opioid formulations designed to resist/deter abuse. Drugs (2010) 1.29
Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther (2001) 1.19
What have we learned from OxyContin? J Pain Palliat Care Pharmacother (2003) 1.06
Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs (2009) 1.05
Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag (2009) 1.03
Total necrosis of the intranasal structures and soft palate as a result of nasal inhalation of crushed OxyContin. Ear Nose Throat J (2005) 0.97
Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. J Clin Pharmacol (2011) 0.95
Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Pain Med (2012) 0.91
Development of tamper deterrent formulations: state of the pharmaceutical industry. Curr Drug Abuse Rev (2010) 0.91
A brief survey to characterize oxycodone abuse patterns in adolescents enrolled in two substance abuse recovery high schools. Am J Drug Alcohol Abuse (2012) 0.83
Oxycodone extended-release using gel-cap technology to resist alteration and abuse for the treatment of moderate-to-severe pain. Pain Manag (2011) 0.82
Influence of fillers in powder formulations containing N-acetyl-L-cysteine on nasal peptide absorption. J Control Release (2007) 0.82
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin Pharmacol Ther (2003) 3.39
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain (2007) 2.07
Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics (2005) 2.02
ArrayTrack: an FDA and public genomic tool. Methods Mol Biol (2009) 1.71
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
Pharmacokinetics of anthocyanins and ellagic acid in healthy volunteers fed freeze-dried black raspberries daily for 7 days. J Clin Pharmacol (2005) 1.41
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol (2013) 1.16
Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol (2013) 0.95
Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol (2013) 0.93
atBioNet--an integrated network analysis tool for genomics and biomarker discovery. BMC Genomics (2012) 0.85
Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system. Clin Drug Investig (2012) 0.84
Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects. J Clin Pharmacol (2006) 0.83
A study of 17beta-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy. Maturitas (2007) 0.83
Are normal healthy research volunteers psychologically healthy? A pilot investigation. Exp Clin Psychopharmacol (2007) 0.81
Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. J Clin Pharmacol (2013) 0.79
Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. J Pain Symptom Manage (2012) 0.78
Serum transaminase levels should be measured immediately prior to dosing in early phase I clinical trials. J Clin Pharmacol (2010) 0.78
An Open-Label Randomized Crossover Trial of Lyophilized Black Raspberries on Postprandial Inflammation in Older Overweight Males: A Pilot Study. Am J Ther (2016) 0.77
Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects. Drugs Aging (2014) 0.77
Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol (2010) 0.76
The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol (2002) 0.76
SNPTrack™ : an integrated bioinformatics system for genetic association studies. Hum Genomics (2012) 0.75
Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users. Clin Drug Investig (2014) 0.75
Fatality after an injection of Bicillin into the tonsillar fossa during an adenotonsillectomy. Otolaryngol Head Neck Surg (2002) 0.75
Gallium nitrate: effects on cartilage during limb regeneration in the axolotl, Ambystoma mexicanum. J Exp Zool (2002) 0.75